Rebecca Robbins | The Seattle Times

April 22, 2022 at 5:53 pm

Drive to vaccinate the world against COVID is losing steam

There is a growing sense of resignation among public health experts that high COVID vaccination coverage may never be achieved in most lower-income countries.

March 25, 2022 at 7:35 pm

Antibody drug restricted in Northeast as subvariant spreads

The move, likely to extend to other parts of the country as BA.2 spreads, leaves doctors in the Northeast with one fewer option to treat...

February 11, 2022 at 12:30 pm

Monoclonal antibody drug from Eli Lilly gets emergency authorization

The federal government has ordered 600,000 doses of the treatment, which is meant for high-risk COVID patients early in their illness.

Nation & World

Benzie-Leelanau District Health Department registered nurse Dawn Hynds draws a dose of the Johnson & Johnson Covid-19 vaccine during a community vaccination event at Northport Public School in Northport on Thursday, September 16, 2021.

February 8, 2022 at 9:00 pm

J&J pauses production of its COVID vaccine despite persistent need

A crucial Johnson & Johnson plant has stopped making its Covid vaccine, though the company says it has millions of doses in inventory.

Business

January 22, 2022 at 8:56 am

When my mom got COVID, I went searching for Pfizer’s pills

Demand for the drugs is surging as the omicron variant of the coronavirus infects record numbers of Americans. But supplies are scarce.

Louis Shantzek, a retiree who tested positive for COVID and was told he was not eligible for monoclonal antibodies because he had three doses of a vaccine, at home in Miami, Jan. 3, 2022. Supplies of potentially life-saving COVID treatments are extremely limited. “It’s like being told, ‘You’re doing everything you’re supposed to do, but yet we’re not going to help you,

January 6, 2022 at 3:29 pm

Lifesaving COVID treatments face rationing as virus surges again in U.S.

At the onset of the pandemic, scarce ventilators and protective equipment faced strict rationing. Today, as the coronavirus rages into its third year, another precious...

In an image provided by Pfizer, doses of Paxlovid, a coronavirus disease pill, manufactured at Pfizer’s facility in Ascoli, Italy. Two new studies from British researchers suggest that omicron infections more often result in mild illness, compared with previous variants, offering hope that the current surge may not be quite as catastrophic as feared. (Pfizer via The New York Times) — NO SALES; FOR EDITORIAL USE ONLY WITH VIRUS SEVERITY BY ZIMMER OF DEC. 22, 2021. ALL OTHER USE PROHIBITED. — XNYT164 XNYT164

January 4, 2022 at 1:17 pm

U.S. government doubles its order for Pfizer’s COVID pills

The U.S. government doubled its order for Pfizer’s COVID pills Tuesday, a move that will modestly increase the nation’s limited supplies of the treatment in...

Nation & World

December 22, 2021 at 4:01 pm

FDA clears Pfizer’s COVID-19 pills for high-risk patients 12 and older

Paxlovid appears to be substantially more effective than a similar antiviral pill from Merck, known as molnupiravir, that is still awaiting authorization by the FDA.

Nation & World

FILE – A COVID patient monoclonal antibody treatments in Anchorage, Alaska, Oct. 25, 2021. Most of the nation’s antibody drugs may not work for cases of the newly dominant omicron variant; some hospitals have already stopped using them. (Ash Adams/The New York Times) LH184 LH184

December 21, 2021 at 5:58 pm

Hospitals scramble as antibody treatments fail against omicron

The single remaining monoclonal antibody therapy effective against the omicron variant is now in short supply in the U.S., imperiling an option that doctors and...

Nation & World

** FILE ** The Eli Lilly and Company headquarters in pictured in Indianapolis, in this Jan. 25, 2006 file photo. Pharmaceutical company Eli Lilly and Co. on Thursday issued 2007 earnings estimates that are below Wall Street’s current expectations due to the effect of its pending acquisition of Icos Corp. (AP Photo/Darron Cummings, File) NYBZ102

December 3, 2021 at 8:54 pm

FDA authorizes Eli Lilly antibody treatment for high-risk young children

The Food and Drug Administration on Friday authorized Eli Lilly’s monoclonal antibody treatment for infants and children under age 12 with COVID-19 who are at...

Nation & World